Get the Stockscreener App
2.06
6.19%
0.12
Regulus Therapeutics Inc stock is traded at $2.06, with a volume of 1.32M.
It is up +6.19% in the last 24 hours and up +50.36% over the past month.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$1.94
Open:
$1.92
24h Volume:
1.32M
Relative Volume:
1.18
Market Cap:
$126.52M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-1.3038
EPS:
-1.58
Net Cash Flow:
$-27.38M
1W Performance:
+19.77%
1M Performance:
+50.36%
6M Performance:
+35.53%
1Y Performance:
-11.97%
1-Day Range:
$1.92
$2.10
1-Week Range:
$1.63
$2.10
52-Week Range:
$0.8301
$2.90
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Name
Regulus Therapeutics Inc
Sector
Industry
Phone
858-202-6300
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Compare RGLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
2.06 | 126.52M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Mar-18-24 | Initiated | Leerink Partners | Outperform |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Jan-05-18 | Initiated | Leerink Partners | Outperform |
| Jun-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Mar-06-17 | Reiterated | Wedbush | Outperform |
| Jan-30-17 | Downgrade | Needham | Buy → Hold |
| Jan-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Dec-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Nov-02-16 | Reiterated | Needham | Buy |
| Jul-25-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | FBR Capital | Outperform |
| Jun-28-16 | Reiterated | Needham | Buy |
| Jun-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Apr-13-16 | Initiated | Chardan Capital Markets | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Apr-21-15 | Resumed | FBR Capital | Outperform |
| Nov-24-14 | Initiated | Deutsche Bank | Buy |
| Aug-07-14 | Reiterated | FBR Capital | Outperform |
| Aug-14-13 | Reiterated | Needham | Buy |
View All
Regulus Therapeutics Inc Stock (RGLS) Latest News
10 Best Rising Penny Stocks to Buy According to Analysts - Insider Monkey
Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? - Yahoo Finance
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average – Time to Sell? - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - Longview News-Journal
microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st
Regulus Therapeutics (NASDAQ:RGLS) Raised to “Overweight” at Wells Fargo & Company - Defense World
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Quantisnow
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
H.C. Wainwright maintains Buy on Regulus stock, $10 target - Investing.com
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus: Q4 Earnings Snapshot - San Antonio Express-News
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Can Regulus Therapeutics' Conference Appearance Signal New MicroRNA Developments? - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR.com
Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks
Polycystic Kidney Disease Pipeline 2025: FDA Approvals - openPR.com
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Regulus Therapeutics Inc Stock (RGLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):